Inhibitory antibodies of cytokine interleukin 11 dependent signaling pathways

Monoclonal antibodies targeting IL-11 ligand sequences inhibit IL-11 signaling pathways, addressing inflammation and fibrosis in various diseases, providing therapeutic benefits.

WO2026125705A2PCT designated stage Publication Date: 2026-06-18LEAD DISCOVERY CENTER GMBH +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
LEAD DISCOVERY CENTER GMBH
Filing Date
2025-12-12
Publication Date
2026-06-18

AI Technical Summary

⚠Technical Problem

There is a need for antibodies that specifically inhibit the IL-11 dependent signaling cascade, particularly those that bind the IL-11 ligand, as IL-11 levels are implicated in a variety of pathologically affected tissues and have not been effectively addressed by existing technologies.

⚗Method used

Development of monoclonal antibodies or antigen-binding fragments that target the IL-11 ligand with specific CDR sequences, including human or humanized antibodies that bind to the IL-11 receptor complex, inhibiting signaling pathways and cellular responses.

🎯Benefits of technology

The antibodies effectively inhibit IL-11 signaling, reducing inflammation, fibrosis, and abnormal cell proliferation, offering therapeutic potential for conditions such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000044_0001
    Figure IMGF000044_0001
  • Figure IMGF000045_0001
    Figure IMGF000045_0001
  • Figure IMGF000045_0002
    Figure IMGF000045_0002
Patent Text Reader

Abstract

The present invention relates to inhibitory antibodies of cytokine interleukin 11 (IL-11) dependent signaling pathways. Further disclosed are methods for the production of said antibodies, uses in diagnostic, treatment and prevention of IL-11 associated disorders.
Need to check novelty before this filing date? Find Prior Art